GURU.Markets stock price, segment price, and overall market index valuation
The company's share price 2seventy bio Inc.
2seventy bio, spun off from bluebird bio, focuses on cancer cell therapy. Its share price reflects both the commercial success of its approved drug, Abecma, and its high R&D and product development expenditures.
Share prices of companies in the market segment - Oncology cell gene therapy
2seventy bio is a cell and gene therapy company developing drugs to treat cancer. We've categorized it as "Oncology: Cell Therapy." The chart below shows how the market views this complex and capital-intensive biotech sector.
Broad Market Index - GURU.Markets
2seventy Bio is an oncology company developing and commercializing cell therapies for cancer treatment. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with 2seventy's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
TSVT - Daily change in the company's share price 2seventy bio Inc.
2seventy bio, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in cell therapy companies. This metric is a measure of the company's sensitivity to the commercial success of its oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
2seventy bio, a spinoff from bluebird bio, specializes in the development and commercialization of cell therapies for cancer treatment. The cell gene therapy sector is one of the most advanced and volatile in biotech. The chart below reflects the average fluctuations in this industry, serving as a benchmark for TSVT stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
2seventy bio is a biotech company working on cell therapy. Its shares are a bet on scientific breakthroughs. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization 2seventy bio Inc.
2seventy bio, Inc.'s year-over-year performance tells a story about its focus on cell therapy. Its market capitalization over the past 12 months reflects both sales of its approved CAR-T drug, Abecma, and progress in its R&D programs. Its recent decision to divest its R&D business and focus on Abecma was a key strategic development.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
2seventy bio, a spinoff from bluebird bio, is focused on developing cell therapies for cancer. This chart shows how the market views its scientific platform, partnerships, and its path to profitability as a standalone company in the highly competitive oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
2seventy Bio is a company at the forefront of cell therapy, and its shares are driven by lab news. Its year-over-year performance relative to the market isn't about economics, but rather about the hope for a revolution in cancer treatment. The success of its commercial product and developments could boost its stock price, demonstrating a complete breakout from the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization 2seventy bio Inc.
2seventy bio is a company focused on cancer cell therapy. Its monthly performance reflects the commercial success of its Abecma drug (in partnership with Bristol Myers) and progress in its own R&D pipeline.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
2seventy Bio is a biotech company specializing in the development of cell and gene therapies for cancer treatment. The company was spun out of Bluebird Bio. The chart below shows the dynamics of the biotech sector, where cell therapy is one of the most advanced and capital-intensive areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
2seventy bio is a biotechnology company focused on cell and gene therapy for cancer treatment. Its value is determined by the success of its commercial product and development pipeline. Its shares are driven by oncology news and are not correlated with the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization 2seventy bio Inc.
The weekly performance of 2seventy bio, a company focused on cancer cell therapy, reflects the commercial and scientific challenges in this field. Share prices are responding to sales of their approved drug Abecma and progress in developing new cell-based products.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
2seventy Bio is a spinoff from Bluebird Bio, focused on oncology cell therapy. This chart compares its weekly performance with the sector and helps understand how the market views its commercial product, Abecma, and its pipeline of future developments in this competitive field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
2seventy bio is a biotech company working in the cutting-edge field of cell therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does 2seventy bio exist in its own world of clinical trials, or does the overall market environment influence its stock price?
Market capitalization of the company, segment and market as a whole
TSVT - Market capitalization of the company 2seventy bio Inc.
The 2seventy bio market capitalization chart tells the story of a cell therapy-focused company spun out of Bluebird Bio. Its dynamics reflect the company's successful partnership with Bristol Myers Squibb on Abecma. Its trajectory reflects the market's assessment of both its current revenue and the potential of its proprietary developments.
TSVT - Share of the company's market capitalization 2seventy bio Inc. within the market segment - Oncology cell gene therapy
2seventy bio is a company focused on cell and gene therapy for cancer treatment. Its market share reflects the commercial success of its first approved product and the potential for future products. The chart below shows how the market views its leadership in this complex yet promising field.
Market capitalization of the market segment - Oncology cell gene therapy
2seventy Bio is a cancer cell therapy company spun out of Bluebird Bio. The chart below shows the overall market capitalization of this cutting-edge sector. Its volatility reflects both the enormous therapeutic potential and the manufacturing and commercial challenges associated with this complex treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
2seventy bio is a company working in the cutting-edge field of cell and gene therapy. Its market capitalization reflects both its enormous potential and the enormous costs associated with developing these "living drugs." Its performance on the overall chart reflects the pulse of one of the most complex and expensive areas of modern medicine.
Book value capitalization of the company, segment and market as a whole
TSVT - Book value capitalization of the company 2seventy bio Inc.
2seventy bio's book value is its equity and its stake in the commercialization of Abecma's approved CAR-T therapy for multiple myeloma. This is the real, scientific, and commercial foundation behind one of the most advanced technologies in oncology. How has this asset changed? The chart below shows its dynamics.
TSVT - Share of the company's book capitalization 2seventy bio Inc. within the market segment - Oncology cell gene therapy
2seventy bio, spun off from bluebird bio, is focused on cancer cell therapy. The chart shows the share of its advanced manufacturing facilities, reflecting the physical foundation necessary for creating personalized drugs.
Market segment balance sheet capitalization - Oncology cell gene therapy
2seventy, a cell therapy company, is a capital-intensive business. This requires the ownership of advanced R&D centers and in-house production facilities. The BCap_Seg chart for the biotech sector shows that developing breakthrough technologies requires a significant financial base.
Book value of all companies included in the broad market index - GURU.Markets
2seventy bio's capital is its cell therapy platform (CAR-T) for blood cancer treatment, including its commercial product, Abecma. Its assets are its intellectual property and manufacturing partnerships. The chart shows the material weight of this cell therapy-focused biotech.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - 2seventy bio Inc.
2seventy Bio is a spinoff from Bluebird Bio focused on cancer cell therapy. Its balance sheet is based on its technology and partnership with Bristol Myers Squibb. Its market capitalization is based on the commercial success of its already approved drug, Abecma, and the potential of its other developments.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
2seventy bio is a company specializing in cancer cell therapy. Its market valuation on the chart reflects both the commercial success of its approved partner product, Abecma, and the significant investment in developing new, wholly proprietary treatments.
Market to book capitalization ratio for the market as a whole
2seventy bio, Inc. specializes in cell and gene therapy for cancer treatment. Its value is determined by the potential of its advanced technologies. This chart helps assess the market premium for the most innovative and complex biotech areas compared to the economic average.
Debts of the company, segment and market as a whole
TSVT - Company debts 2seventy bio Inc.
2seventy bio, a spinoff from bluebird bio, focuses on cancer cell therapy. It uses the capital to commercialize its approved Abecma product and for R&D. This chart shows how the company finances its expensive operations in the cutting-edge but highly expensive field of oncology.
Market segment debts - Oncology cell gene therapy
2seventy Bio is a cell therapy company spun out of Bluebird Bio. It has one commercial product (Abecma), developed in partnership with Bristol Myers Squibb. This chart shows how the company manages its finances to support product sales and fund the development of new cell therapies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio 2seventy bio Inc.
2seventy Bio is a biotech company spun out of Bluebird Bio and focused on cancer cell therapy. Developing and manufacturing such treatments is extremely expensive. This chart shows how the company funds its cutting-edge but capital-intensive research, reflecting its financial risk on the path to profitability.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
2seventy bio, spun out of bluebird bio, focuses on developing and commercializing cell therapies for cancer, one of the most complex and expensive areas in medicine. The chart shows how aggressively the sector uses debt, providing context for assessing how 2seventy bio finances its capital-intensive technologies.
Debt to book value of all companies in the market
2seventy bio, Inc., a company focused on cell-based gene therapy for cancer, is pursuing extremely expensive developments. This chart, showing the market's overall debt load, helps assess its financial risks. It helps understand how the company's capital raising strategy aligns with the high standards and risks of the advanced biotech sector.
P/E of the company, segment and market as a whole
P/E - 2seventy bio Inc.
2seventy bio is a cell and gene therapy company focused on developing cancer treatments. This chart shows how the market values its research after its spinoff from bluebird bio. This value is dependent on the success of its commercial product, Abecma, and progress in clinical trials.
P/E of the market segment - Oncology cell gene therapy
This is the average P/E for biotech companies focused on cell therapy. For 2seventy bio, a spinoff of Bluebird Bio, this is an important benchmark. It helps investors understand how they view its focused portfolio and its ability to successfully commercialize complex and expensive cancer treatments.
P/E of the market as a whole
2seventy bio is a biotech company spun out of bluebird bio and focused on cell therapy for cancer. Its valuation is a pure bet on the success of its complex and expensive treatments. It is unrelated to the general economic cycles illustrated by this chart. Its fate is decided in the clinics.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company 2seventy bio Inc.
This chart from 2seventy bio, Inc., a cancer cell therapy company, shows market expectations for sales of its approved drug, Abecma. It reflects forecasts for the growth of CAR-T therapy for multiple myeloma and the success of other developments.
%20P%2FE%202seventy%20bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-2seventy-bio-Inc.&v=1772620919032 "Chart of the company's future (projected) P/E 2seventy bio Inc.")
Future (projected) P/E of the market segment - Oncology cell gene therapy
2seventy Bio is a cell and gene therapy company spun out of Bluebird Bio. It develops and commercializes cancer treatments, including Abecma, the approved multiple myeloma drug. This chart shows forecasts for the oncology sector. This helps assess how the market perceives Abecma's commercial success and the potential of the company's other developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772620919131 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
2seventy bio, Inc. is a cell and gene therapy company spun out of Bluebird Bio. It is focused on oncology. This chart of overall biotech risk appetite is key for evaluating companies operating at the very cutting edge of science, where the risks and potential rewards are greatest.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772620919193 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit 2seventy bio Inc.
2seventy bio is a cell and gene therapy development and commercialization company spun out of bluebird bio. Its main product is the CAR-T therapy Abecma. This chart shows how the company balances revenue from an already approved drug with high research and manufacturing costs.
Profit of companies in the market segment - Oncology cell gene therapy
2seventy Bio is a cell and gene therapy company that spun out of Bluebird Bio. This chart, which shows the sector's profitability, illustrates how difficult and expensive it is to commercialize these breakthrough treatments. Their Abecma drug for multiple myeloma is one of the first CAR-T therapies approved, but their goal is to make the therapy more accessible.
Overall market profit
2seventy bio is a cancer cell therapy company. It was spun out of Bluebird Bio and is focused on the development and commercialization of CAR-T therapies. Success depends on scientific breakthroughs and the adoption of these expensive treatments. Overall economic stability, as illustrated by the chart, is important for funding such cutting-edge medical technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company 2seventy bio Inc.
2seventy Bio is a cell and gene therapy company spun out of Bluebird Bio. It focuses on developing and commercializing cancer treatments. This chart reflects analysts' forecasts for sales of its approved drug, Abecma, and the success of future oncology developments.
%20profit%20of%20the%20company%202seventy%20bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-2seventy-bio-Inc.&v=1772620919327 "Graph of future (projected) profit of the company 2seventy bio Inc.")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
2seventy bio is a cell and gene therapy company spun out of bluebird bio. Its main commercial product is Abecma's CAR-T therapy for multiple myeloma. Growth depends on the success of this therapy. This biotech chart reflects the overall investor confidence in the potential of cell therapies as a new standard of cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772620919355 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
2seventy bio is a company specializing in cancer cell therapy. Its success depends on scientific breakthroughs and the commercialization of its products. The overall profit forecast, reflected in this chart, impacts the overall health of the healthcare sector and the willingness to pay for expensive innovative treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772620919405 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - 2seventy bio Inc.
2seventy bio is a cell and gene therapy company focused on cancer treatment. This chart shows how investors estimate the revenue from its commercial product, Abecma. It reflects the enormous potential of CAR-T therapy, as well as the high costs and complexities associated with manufacturing and developing these advanced treatments.
P/S market segment - Oncology cell gene therapy
2seventy bio is a cell and gene therapy company spun out of bluebird bio and focused on oncology. The company's revenue is dependent on the success of its commercial product and the development of its clinical programs. This chart reflects the average valuation in the sector, helping to understand how investors value this highly specialized and innovative company.
P/S of the market as a whole
2seventy bio is a cell and gene therapy company spun off from bluebird bio. It is focused on developing and commercializing cancer treatments. This chart, showing average market revenue estimates, helps understand the premium investors are willing to pay for cutting-edge oncology technologies that offer a cure.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company 2seventy bio Inc.
2seventy Bio is a biotechnology company specializing in the development of cell therapies for cancer treatment. It was spun out of Bluebird Bio and, together with Bristol Myers Squibb, markets Abecma's CAR-T therapy. This chart reflects investor expectations for Abecma's future sales growth and the success of its other cell therapy programs.
%20P%2FS%202seventy%20bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-2seventy-bio-Inc.&v=1772620919493 "The graph of the company's future (projected) P/S 2seventy bio Inc.")
Future (projected) P/S of the market segment - Oncology cell gene therapy
2seventy bio, Inc. is a cell and gene therapy company focused on creating transformative medicines for oncology. The company was spun off from bluebird bio. This chart shows the average estimated future sales in the gene therapy sector. It helps understand how the market views 2seventy bio's scientific potential and commercial prospects.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772620919549 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
2seventy bio is a cell and gene therapy company spun out of bluebird bio. This chart shows overall market revenue forecasts. The company is focused on developing and commercializing transformative cancer treatments, and its success is a key part of advancing this cutting-edge field of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772620919615 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales 2seventy bio Inc.
This chart shows the revenue of 2seventy bio, a cell therapy company. Its primary source of income is its share of sales of Abecma, a drug developed jointly with Bristol Myers Squibb for the treatment of multiple myeloma. The trend reflects the commercial success of this cutting-edge therapy.
Sales of companies in the market segment - Oncology cell gene therapy
2seventy bio is a cell and gene therapy company focused on the development and commercialization of cancer treatments. This chart reflects the growth of the oncology market. The company, a spinoff from Bluebird Bio, is a pioneer in CAR-T therapy, and its products and developments are at the forefront of the fight against hematological malignancies.
Overall market sales
2seventy bio is a cell and gene therapy company focused on cancer treatment. Its success depends on the commercialization of its products and progress in research. The overall economic situation, shown in this chart, affects the availability of capital to fund such capital-intensive developments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company 2seventy bio Inc.
2seventy bio is a company focused entirely on the development and commercialization of cell and gene therapies for cancer. Its primary revenue comes from Abecma. This chart shows analysts' expectations for the sales of this innovative drug and its pipeline development.
%20sales%20of%20the%20company%202seventy%20bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-2seventy-bio-Inc.&v=1772620919784 "Schedule of future (projected) sales of the company 2seventy bio Inc.")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
2seventy Bio is a cell and gene therapy company spun out of Bluebird Bio. It is focused on developing and commercializing transformative cancer treatments. This chart shows the forecast for the entire oncology market, where cell therapies like 2seventy's are one of the most powerful and promising areas.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772620919870 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
2seventy bio is a cell and gene therapy company spun out of bluebird bio and focused on oncology. Its success depends on sales of its commercial product and R&D results. This graph, reflecting the investment climate in biopharma, impacts the company's valuation and its ability to fund the development of next-generation cell therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772620919927 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality 2seventy bio Inc.
2seventy bio is a biotech company spun out of bluebird bio and focused on developing and commercializing cell therapies for cancer. Its profitability depends on the success of its CAR-T therapy, Abecma. This chart shows the financial results of the company, which is trying to build a sustainable business around one of the most advanced and expensive treatments in the world.
Market segment marginality - Oncology cell gene therapy
2seventy bio is a cell and gene therapy company spun off from bluebird bio. It specializes in developing and commercializing cancer treatments. Profitability depends on the success of their lead product, Abecma, and progress in research. This chart shows the financial results of their operations at the forefront of oncology.
Market marginality as a whole
2seventy bio is a cell therapy company spun out of bluebird bio. They are focused on developing and commercializing CAR-T therapy for the treatment of blood cancers. This overall profitability schedule is not important to them. Their success depends on the commercial success of their approved Abecma product and the advancement of other cell therapies in development.
Employees in the company, segment and market as a whole
Number of employees in the company 2seventy bio Inc.
2seventy bio is a cancer cell therapy company spun out of bluebird bio. Its staff consists of scientists and specialists in the production of complex cell products. This schedule reflects the labor-intensive and science-intensive nature of its cutting-edge treatment methods.
Share of the company's employees 2seventy bio Inc. within the market segment - Oncology cell gene therapy
2seventy bio is a company fully focused on the development and commercialization of cell therapies for cancer treatment. This chart reflects its focus. It shows the significant proportion of scientists and clinicians in this niche field that 2seventy bio employs, underscoring its commitment to being a leader in this revolutionary field of medicine.
Number of employees in the market segment - Oncology cell gene therapy
2seventy bio, Inc. is a cell and gene therapy company focused on cancer treatment. This chart illustrates employment trends in the oncology sector. The growth in scientists and manufacturing specialists reflects the commercialization of one of the first approved CAR-T therapies and the company's efforts to develop next-generation treatments for blood cancers.
Number of employees in the market as a whole
2seventy bio is a company specializing in cell and gene therapy for cancer. Its success depends on scientific breakthroughs and the commercialization of complex treatments. The overall economic environment, reflected in this chart, affects the availability of capital and the solvency of the healthcare system, which must cover very expensive therapies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company 2seventy bio Inc. (TSVT)
2seventy bio is a biotech company focused on cellular gene therapy (CAR-T) for cancer treatment (a spinoff of Bluebird Bio). This is one of the most complex areas of R&D. The chart shows the market value of their lead product (Abecma) and their scientific platform. The high cost per employee reflects the enormous value of their intellectual property.
%20of%20the%20company%202seventy%20bio%20Inc.%20(TSVT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-2seventy-bio-Inc.-TSVT&v=1772620920290 "Chart of market capitalization per employee (in thousands of dollars) of the company 2seventy bio Inc. (TSVT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
2seventy bio is a cell and gene therapy company focused on cancer treatment. Like many cutting-edge biotechs, its value is determined by its scientific platform and clinical trial results. This chart shows the high valuation of its intellectual property relative to its scientific team.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772620920378 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
2seventy bio is a cell and gene therapy company spun out of bluebird bio. The chart shows a valuation at the forefront of biotech. The very high market capitalization per employee reflects the enormous potential and complexity of their cancer treatment technologies, which require deep scientific expertise.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772620920467 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company 2seventy bio Inc. (TSVT)
2seventy Bio is a biotech company spun out of Bluebird Bio, focused entirely on cancer cell therapy. Their flagship product is Abecma (in partnership with BMS), an approved CAR-T therapy. This chart illustrates the balance: Abecma's massive revenues must cover the enormous R&D costs of developing future cell therapies.
%20Chart%202seventy%20bio%20Inc.%20(TSVT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-2seventy-bio-Inc.-TSVT&v=1772620920586 "Company Profit Per Employee (in thousands of dollars) Chart 2seventy bio Inc. (TSVT)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
2seventy bio is a biotech company spun out of bluebird bio, focused on cell therapy for cancer. Their key product is Abecma (in partnership with Bristol Myers). This metric reflects the balance between commercial product revenue and high R&D costs.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772620920613 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
2seventy Bio (TSVT) is a biotech company (spinned out of Bluebird Bio) specializing in cancer cell therapy (CAR-T). They have an approved drug (Abecma, with BMS). This chart shows how much their share of Abecma's profits covers the enormous R&D costs of developing new cell therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772620920632 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee 2seventy bio Inc. (TSVT)
2seventy bio is a cell and gene therapy company spun out of bluebird bio. This chart reflects the commercial success of its approved drug for the treatment of multiple myeloma. The increase in revenue per employee reflects the high cost and complexity of the therapy, as well as demand from cancer centers.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-2seventy-bio-Inc.-TSVT&v=1772620920652 "Sales chart per company employee 2seventy bio Inc. (TSVT)")
Sales per employee in the market segment - Oncology cell gene therapy
2seventy bio (TSVT) is a cancer cell therapy company (spinned out of Bluebird Bio). Their key asset is Abecma, an approved CAR-T therapy for multiple myeloma. This chart shows how much revenue (from sales and Abecma royalties) each employee (scientist, production technician) generates.
Sales per employee for the market as a whole
2seventy Bio (TSVT) is a biotech company focused on cancer cell therapy. The company was spun out of Bluebird Bio and has a commercial product (Abecma). This chart shows how successfully the company generates revenue from its complex and expensive drug while covering its enormous R&D costs.
Short shares by company, segment and market as a whole
Shares shorted by company 2seventy bio Inc. (TSVT)
2seventy Bio is a cell therapy company (CAR-T) for cancer treatment, spun out of Bluebird Bio. The bearish sentiment shown in this chart reflects investor bets that its treatments are too expensive and complex to achieve widespread commercial success, and that its pipeline is risky.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-2seventy-bio-Inc.-TSVT&v=1772620920815 "Short Shares Chart for the Company 2seventy bio Inc. (TSVT)")
Shares shorted by market segment - Oncology cell gene therapy
2seventy bio (TSVT) is a company entirely dedicated to cell gene therapy, specifically the development of CAR-T cancer treatments. This is one of the most technologically complex areas of medicine. This chart shows the overall bearish bets against the entire cell therapy sector. The high figure suggests that investors see enormous risks in the commercialization and production of these "living drugs."
Shares shorted by the overall market
2seventy bio operates at the cutting edge of science—in cell and gene therapy. This involves incredibly expensive R&D. This chart measures general fear. When investors are afraid, they are reluctant to fund the most expensive "research projects." They sell off TSVT shares, fearing the company won't have enough capital to complete trials in a market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator 2seventy bio Inc. (TSVT)
2seventy bio (TSVT) is a cell gene therapy company spun off from bluebird bio. Its flagship product is Abecma, a CAR-T therapy for myeloma. This indicator measures momentum. It shows when the stock is "overheated" (above 70) on Abecma's sales report or "oversold" (below 30) due to production difficulties.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-2seventy-bio-Inc.-TSVT&v=1772620920979 "RSI 14 indicator chart for the company's stock 2seventy bio Inc. (TSVT)")
RSI 14 Market Segment - Oncology cell gene therapy
2seventy bio (a spinoff of Bluebird bio) is a pure-play player in *cell therapy*. Their focus is *CAR-T* therapy (Abecma) for the treatment of *myeloma*. The "Oncology cell gene therapy" sector (biotech) thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It helps us understand: is TSVT's growth a niche product, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
2seventy bio (TSVT) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TSVT (2seventy bio Inc.)
2seventy bio (TSVT) is a company focused on cancer cell therapy. Their primary asset is Abecma, a CAR-T therapy for myeloma (developed with BMS). This chart shows the analysts' average 12-month forecast. It reflects their view on Abecma's commercial success and the potential of their R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TSVT-2seventy-bio-Inc.&v=1772620921189 "A chart showing analyst consensus forecasts for the expected stock price. TSVT (2seventy bio Inc.)")
The difference between the consensus estimate and the actual stock price TSVT (2seventy bio Inc.)
2seventy bio (TSVT) is a pure-play cell therapy company (a Bluebird spinoff). Their flagship product is Abecma (CAR-T for myeloma), developed with BMS. This chart shows how far the current share price differs from the "fair" value. It reflects analysts' views on their R&D portfolio and their ability to compete in the CAR-T race.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TSVT-2seventy-bio-Inc.&v=1772620921249 "A chart showing the difference between the consensus forecast and the actual stock price. TSVT (2seventy bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
2seventy bio (TSVT) is a pure-play R&D company spun out of Bluebird Bio. It focuses on developing innovative cell therapies (CAR-T) for cancer treatment. This chart shows general expectations for the oncology sector, reflecting whether experts believe in the future of "next-generation" CAR-T.
Analysts' consensus forecast for the overall market share price
2seventy bio (TSVT) is a "living" cancer drug. This company (a spinoff of bluebird) is commercializing Abecma, an approved CAR-T therapy that "reprograms" a patient's cells to fight cancer. This chart shows the overall risk appetite, reflecting how much investors believe the healthcare system is willing to pay millions for these breakthrough technologies.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index 2seventy bio Inc.
2seventy bio (a spinoff from bluebird bio) is fully focused on the development and commercialization of cell-based gene therapy in oncology, including the already approved Abecma drug. This chart is a composite index assessing Abecma's commercial success, the potential of other developments, and the high operational and financial risks associated with expensive cell therapy.
AKIMA Market Segment Index - Oncology cell gene therapy
2semicon (TSVT) is a cell and gene therapy oncologist. It is a spinoff of Bluebird Bio, focused entirely on developing and selling CAR-T therapies for blood cancers (Abecma). This chart compares their composite index to the sector average.
The AKIM Index for the overall market
2seventy bio is an oncology company spun out of bluebird bio. It is a BMS partner on Abecma and has refocused on a capital-conserving model. This chart, which reflects the market average, provides a macro backdrop. It helps assess how TSVT, a commercial CAR-T company, compares to overall economic trends.
